British Journal of Pharmacology,
Journal Year:
2017,
Volume and Issue:
174(19), P. 3242 - 3256
Published: March 8, 2017
Learning
to
associate
cues
or
contexts
with
potential
threats
rewards
is
adaptive
and
enhances
survival.
Both
aversive
appetitive
memories
are
therefore
powerful
drivers
of
behaviour,
but
the
inappropriate
expression
conditioned
responding
fear‐
drug‐related
stimuli
can
develop
into
anxiety‐related
substance
abuse
disorders
respectively.
These
associated
abnormally
persistent
emotional
inadequate
treatment,
often
leading
symptom
relapse.
Studies
show
that
cannabidiol,
main
non‐psychotomimetic
phytocannabinoid
found
in
Cannabis
sativa
,
reduces
anxiety
via
5‐HT
1A
(indirect)
cannabinoid
receptor
activation
paradigms
assessing
innate
responses
threat.
There
also
accumulating
evidence
from
animal
studies
investigating
effects
cannabidiol
on
fear
memory
processing
indicating
it
learned
translationally
relevant
phobias
post‐traumatic
stress
disorder.
Cannabidiol
does
so
by
reducing
acutely
disrupting
reconsolidation
enhancing
extinction,
both
which
result
a
lasting
reduction
fear.
Recent
have
begun
elucidate
drug
using
translational
relevance
addiction.
The
findings
suggest
their
reconsolidation.
Here,
we
review
literature
demonstrating
anxiolytic
before
focusing
its
various
processes.
Understanding
how
regulates
emotion
may
eventually
lead
use
as
treatment
for
disorders.
Linked
Articles
This
article
part
themed
section
Pharmacology
Cognition:
Panacea
Neuropsychiatric
Disease?
To
view
other
articles
this
visit
http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc
BMC Psychiatry,
Journal Year:
2020,
Volume and Issue:
20(1)
Published: Jan. 16, 2020
Medicinal
cannabis
has
received
increased
research
attention
over
recent
years
due
to
loosening
global
regulatory
changes.
been
reported
have
potential
efficacy
in
reducing
pain,
muscle
spasticity,
chemotherapy-induced
nausea
and
vomiting,
intractable
childhood
epilepsy.
Yet
its
application
the
field
of
psychiatry
is
lesser
known.The
first
clinically-focused
systematic
review
on
emerging
medical
across
all
major
psychiatric
disorders
was
conducted.
Current
evidence
regarding
whole
plant
formulations
plant-derived
cannabinoid
isolates
mood,
anxiety,
sleep,
psychotic
deficit/hyperactivity
disorder
(ADHD)
discussed;
while
also
detailing
clinical
prescription
considerations
(including
pharmacogenomics),
occupational
public
health
elements,
future
recommendations.
The
literature
conducted
during
2019,
assessing
data
from
case
studies
trials
involving
medicinal
or
for
(neurological
conditions
pain
were
omitted).The
present
therapeutics
nascent,
thereby
it
currently
premature
recommend
cannabinoid-based
interventions.
Isolated
positive
have,
however,
revealed
tentative
support
cannabinoids
(namely
cannabidiol;
CBD)
social
anxiety;
with
mixed
(mainly
positive)
adjunctive
use
schizophrenia.
Case
suggest
that
may
be
beneficial
improving
sleep
post-traumatic
stress
disorder,
however
weak.
Preliminary
findings
indicate
no
benefit
depression
high
delta-9
tetrahydrocannabinol
(THC)
therapeutics,
CBD
mania.
One
isolated
study
indicates
some
an
oral
cannabinoid/terpene
combination
ADHD.
Clinical
prescriptive
consideration
involves
caution
high-THC
(avoidance
youth,
people
anxiety
disorders),
gradual
titration,
regular
assessment,
cardiovascular
respiratory
disorders,
pregnancy
breast-feeding.There
encouraging,
albeit
embryonic,
treatment
a
range
disorders.
Supportive
are
key
isolates,
clinicians
need
mindful
safety
considerations,
especially
if
initiating
higher
dose
THC
formulas.
Pharmacology Research & Perspectives,
Journal Year:
2020,
Volume and Issue:
8(6)
Published: Nov. 9, 2020
Abstract
Cannabidiol
(CBD)
is
the
second
most
abundant
component
of
Cannabis
plant
and
known
to
have
effects
distinct
from
Δ
9
‐tetrahydrocannabinol
(THC).
Many
studies
that
examined
behavioral
CBD
concluded
it
lacks
psychotomimetic
attributed
THC.
However,
was
shown
a
broad
spectrum
on
several
conditions
such
as
anxiety,
inflammation,
neuropathic
pain,
epilepsy.
It
currently
thought
engages
different
targets
hence
CBD’s
are
be
due
multiple
molecular
mechanisms
action.
A
well‐accepted
set
include
GPCRs
ion
channels,
with
serotonin
5‐HT
1A
receptor
transient
potential
cation
channel
TRPV1
being
two
main
targets.
has
also
been
target
G
protein‐coupled
receptors
(GPCRs)
cannabinoid
opioid
receptors.
Other
suggested
role
for
additional
channels
CBD.
Currently,
clinical
efficacy
not
completely
understood.
Evidence
derived
randomized
trials,
in
vitro
vivo
models
real‐world
observations
support
use
drug
treatment
option
neuropathy,
many
other
conditions.
Hence
an
understanding
current
status
field
relates
great
interest
so,
this
review,
we
findings
recent
highlight
these
Basic & Clinical Pharmacology & Toxicology,
Journal Year:
2022,
Volume and Issue:
130(4), P. 439 - 456
Published: Jan. 27, 2022
Cannabidiol
(CBD)
is
an
abundant
non-psychoactive
phytocannabinoid
in
cannabis
extracts
which
has
high
affinity
on
a
series
of
receptors,
including
Type
1
cannabinoid
receptor
(CB1),
2
(CB2),
GPR55,
transient
potential
vanilloid
(TRPV)
and
peroxisome
proliferator-activated
gamma
(PPARγ).
By
modulating
the
activities
these
CBD
exhibits
multiple
therapeutic
effects,
neuroprotective,
antiepileptic,
anxiolytic,
antipsychotic,
anti-inflammatory,
analgesic
anticancer
properties.
could
also
be
applied
to
treat
or
prevent
COVID-19
its
complications.
Here,
we
provide
narrative
review
CBD's
applications
human
diseases:
from
mechanism
action
clinical
trials.
Current Neuropharmacology,
Journal Year:
2019,
Volume and Issue:
18(2), P. 87 - 96
Published: Sept. 4, 2019
Mood
disorders
are
the
most
prevalent
mental
conditions
encountered
in
psychiatric
practice.
Numerous
patients
suffering
from
mood
present
with
treatment-resistant
forms
of
depression,
co-morbid
anxiety,
other
and
bipolar
disorders.
Standardized
essential
oils
(such
as
that
Lavender
officinalis)
have
been
shown
to
exert
clinical
efficacy
treating
anxiety
As
endocannabinoids
suggested
play
an
important
role
major
generalized
disorders,
Cannabis
sativa
was
for
their
treatment.
The
endocannabinoid
system
is
widely
distributed
throughout
body
including
brain,
modulating
many
functions.
It
involved
related
its
activity
may
be
modified
by
exogenous
cannabinoids.
CB1
CB2
receptors
primarily
serve
binding
sites
well
phytocannabinoids,
produced
cannabis
inflorescences.
However,
‘cannabis’
not
a
single
compound
product
but
known
complicated
molecular
profile,
producing
plethora
phytocannabinoids
alongside
vast
array
terpenes.
Thus,
“entourage
effect”
positive
contribution
derived
addition
terpenes
Here,
we
review
literature
on
effects
cannabinoids
discuss
possibility
enhancing
cannabinoid
symptoms
terpenoids.
Possible
underlying
mechanisms
anti-depressant
anxiolytic
reviewed.
These
natural
products
potential
source
new
medications
treatment
Current Neuropharmacology,
Journal Year:
2018,
Volume and Issue:
17(8), P. 710 - 736
Published: Aug. 27, 2018
Background:
Obsessive-compulsive
disorder
(OCD)
is
associated
with
affective
and
cognitive
symptoms
causing
personal
distress
reduced
global
functioning.
These
have
considerable
societal
costs
due
to
healthcare
service
utilization.
Objective:
Our
aim
was
assess
the
efficacy
of
pharmacological
interventions
in
OCD
clinical
guidelines,
providing
a
comprehensive
overview
this
field.
Methods:
We
searched
PubMed
database
for
papers
dealing
drug
treatment
OCD,
specific
focus
on
treatments
antidepressants,
antipsychotics,
mood
stabilizers,
off-label
medications,
pharmacogenomics.
Results:
Prolonged
administration
selective
serotonin
reuptake
inhibitors
(SSRIs)
most
effective.
Better
results
can
be
obtained
SSRI
combined
behavioral
therapy
(CBT)
or
similarly
oriented
exposure
response
prevention
(ERP).
Refractory
could
treated
different
strategies,
including
switch
another
clomipramine,
augmentation
an
atypical
antipsychotic.
The
addition
medications
other
than
antipsychotics
intravenous
antidepressant
needs
further
investigation,
as
evidence
inconsistent.
Pharmacogenomics
personalization
reduce
resistance.
Conclusion:
SSRI/clomipramine
combination
CBT/ERP
optimal
compared
each
alone
treatments.
New
strategies
refractory
are
needed.
role
pharmacogenomics
become
preponderant
coming
years.
Frontiers in Psychology,
Journal Year:
2019,
Volume and Issue:
10
Published: Nov. 8, 2019
Accumulated
evidence
indicates
that
cannabidiol
(CBD),
a
nonpsychotomimetic
and
nonaddictive
main
component
of
the
Cannabis
sativa
plant,
reverses
anxiety-like
behavior.
The
purpose
present
study
was
to
assess
efficacy
CBD
treatment
for
Japanese
late
teenagers
with
social
anxiety
disorder
(SAD).
Thirty-seven
18-19-year-old
SAD
avoidant
personality
received,
in
double-blind
study,
cannabis
oil
(n
=
17)
containing
300
mg
or
placebo
20)
daily
4
weeks.
symptoms
were
measured
at
beginning
end
period
using
Fear
Negative
Evaluation
Questionnaire
Liebowitz
Social
Anxiety
Scale.
significantly
decreased
by
both
scales.
results
indicate
could
be
useful
option
treat
anxiety.
Pain,
Journal Year:
2021,
Volume and Issue:
162(1), P. S5 - S25
Published: March 15, 2021
This
narrative
review
represents
an
output
from
the
International
Association
for
Study
of
Pain's
global
task
force
on
use
cannabis,
cannabinoids,
and
cannabis-based
medicines
pain
management,
informed
by
our
companion
systematic
meta-analysis
preclinical
studies
in
this
area.
Our
aims
are
(1)
to
describe
value
studying
cannabinoids
endogenous
cannabinoid
(endocannabinoid)
system
modulators
preclinical/animal
models
pain;
(2)
discuss
both
pain-related
efficacy
additional
pain-relevant
effects
(adverse
beneficial)
endocannabinoid
as
they
pertain
animal
pathological
or
injury-related
persistent
(3)
identify
important
directions
future
research.
In
service
these
goals,
provides
overview
pharmacology
modulators,
with
specific
relevance
describes
pharmacokinetics
rodents
humans;
highlights
differences
discrepancies
between
clinical
Preclinical
(rodent)
have
advanced
understanding
underlying
sites
mechanisms
action
suppressing
nociceptive
signaling
behaviors.
We
conclude
that
substantial
evidence
supports
contention
hold
considerable
promise
analgesic
drug
development,
although
challenge
translating
knowledge
into
clinically
useful
is
not
be
underestimated.